SECsense Logo

Grace Therapeutics 10-Q/A: Q3 2024 Financial Insights on NASDAQ GRCE

$GRCE
Form 10-Q/A
Filed on: 2025-02-19
Source
Grace Therapeutics 10-Q/A: Q3 2024 Financial Insights on NASDAQ GRCE

Based on the provided section of the financial report, here are the key insights and important information extracted:

  1. Entity Information:
  • Company Name: Grace Therapeutics, Inc.
  • CIK Number: 0001444192
  • IRS Employer Identification Number: 98-1359336
  • Address: 103 Carnegie Center Suite 300, Princeton, NJ 08540
  • Contact Number: 609-322-1602
  1. Stock Information:
  • Common Stock Par Value: $0.0001 per share
  • Ticker Symbol: GRCE
  • Exchange: NASDAQ
  1. Filing Details:
  • Filing Type: 10-Q/A (Amended Quarterly Report)
  • Filing Period: Q3 for the period ending December 31, 2024
  • Filing Date: February 12, 2025
  • Filer Status: Non-accelerated Filer
  1. Period Context:
  • Reporting Period:
    • Start Date: April 1, 2024
    • End Date: December 31, 2024
  1. Shares Information:
  • Total Shares Outstanding: 13,416,735 shares
  1. Filing Compliance:
  • The report indicates that the filing is compliant with SEC regulations, classified as true for the necessary requirements.

Summary:

Grace Therapeutics, Inc. is a non-accelerated filer with a par value of common stock set at $0.0001 per share and a total of approximately 13.42 million shares outstanding. The company operates under the NASDAQ exchange using the ticker GRCE. The latest filing was an amended quarterly report for Q3, detailing the financial performance for the period ending December 31, 2024.